40332-16-9

Basic information

• Product Name: BENZOIMIDAZOL-1-YL-ACETIC ACID
• Synonyms: TIMTEC-BB SBB010151;2-(BENZIMIDAZOLE-1-YL)-ACETIC ACID;2-(1H-BENZIMIDAZOL-1-YL)ACETIC ACID;1-(CARBOXYMETHYL) BENZIMIDAZOLE;1H-BENZIMIDAZOL-1-YLACETIC ACID;AKOS MSC-0005;BENZOIMIDAZOL-1-YL-ACETIC ACID;IFLAB-BB F0356-0370
• CAS NO: 40332-16-9
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17
• Product Categories: BENZIMIDAZOLE;pharmacetical
• Mol File: 40332-16-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 406.3°Cat760mmHg
• Flash Point: 199.5°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 2.49E-07mmHg at 25°C
• Refractive Index: 1.65
• CAS DataBase Reference: BENZOIMIDAZOL-1-YL-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIMIDAZOL-1-YL-ACETIC ACID(40332-16-9)
• EPA Substance Registry System: BENZOIMIDAZOL-1-YL-ACETIC ACID(40332-16-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 40332-16-9(Hazardous Substances Data)

Usage

Description

BENZOIMIDAZOL-1-YL-ACETIC ACID, also known as BIAA, is a chemical compound that exhibits potential therapeutic applications. As a derivative of imidazole and acetic acid, BIAA has demonstrated promise as a treatment for neurological and psychiatric disorders. It possesses potential anti-seizure and neuroprotective effects, and may also exhibit antidepressant and anxiolytic properties. Ongoing research is aimed at fully understanding BIAA's potential uses and benefits, highlighting its promise as a compound for medical applications in treating a range of neurological and psychiatric conditions.

Uses

Used in Pharmaceutical Industry:
BIAA is used as a potential therapeutic agent for neurological and psychiatric disorders due to its demonstrated anti-seizure and neuroprotective effects. It is being studied for its potential to treat various conditions, including but not limited to, epilepsy and neurodegenerative diseases.
Used in Neurological Treatments:
BIAA is used as a neuroprotective agent for its potential to protect neurons from damage, which could be beneficial in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's.
Used in Psychiatric Treatments:
BIAA is used as a potential antidepressant and anxiolytic, suggesting its utility in managing mood disorders and anxiety-related conditions.
Used in Research and Development:
BIAA is used as a subject of ongoing research to explore its full potential and understand its mechanisms of action, with the aim of developing new treatments for neurological and psychiatric disorders.

InChI:InChI=1/C9H8N2O2/c12-9(13)5-11-6-10-7-3-1-2-4-8(7)11/h1-4,6H,5H2,(H,12,13)

Upstream product

• 4414-74-8 2-(1H-benzo[d]imidazol-1-yl)acetonitrile 
• 51-17-2 benzoimidazole 
• 7748-25-6 potassium chloroacetate 
• 79-08-3 bromoacetic acid 
• 503140-97-4 benzimidazol-1-ylacetic acid benzyl ester 
• 55175-50-3 1-(ethoxycarbonylmethyl)benzimidazole 
• 79-11-8 chloroacetic acid 

Downstream Products

• 6340-03-0 2-(1H-benzo[d]imidazol-1-yl)ethanol 
• 157198-80-6 Benzoimidazol-1-yl-acetyl chloride 
• 1355446-05-7 2-(2-(1H-benzo[d]imidazol-1-yl)-N-(3-fluorophenyl)acetamido)-N-cyclopentyl-2-o-tolylacetamide 
• 6122-05-0 2-benzoimidazol-1-yl-N-[4-(4-chloro-phenyl)-thiazol-2-yl]-acetamide 

Relevant articles and documents

Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1

Different N-heteroaryl compounds bearing pyrimidine and benzimidazole moieties have been designed in silico using Discovery studio 2.5 software, synthesized and evaluated for their inhibitory activity as reverse transcriptase inhibitors against HIV-1 replication using laboratory adapted strains HIV-1IIIB (X4, subtype B) and HIV-1Ada5 (R5, subtype B), and the primary isolates HIV-1UG070 (X4, subtype D) and HIV-1VB59 (R5, subtype C). Cell-based assay showed that compounds were active at 1.394 μM concentrations (Selectivity Index: 1.29-38.39). The studies on structure-activity relationship clearly suggested anti-HIV activity of pyrimidine and benzimidazole derivatives and these findings were consistent with the in vitro cell-based experimental data. The results of molecular modeling and docking confirmed that all compounds assumed a butterfly-like conformation and showed H-bond, 'π-π' and 'π-+' and hydrophobic interactions within flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase, similar to known non-nucleoside reverse transcriptase inhibitors, such as nevirapine. In view of the results obtained, it can be said that the chemical skeletons of N, N′-bis-(pyridin-2-yl)-succinamide (14 and 15) and 1, 4-bis-benzoimidazol-1-yl-butane-1, 4-dione (16 and 17) may be used for developing potent inhibitors of HIV-1 replication, with suitable structure/pharmacophore modifications.

Analgesic and anti-inflammatory activity of new analogs of HC-030031: A TRPA1 channel antagonist

One of our study direction is research in the group of compounds affecting the TRPA1 ion channel (Transient receptor potential cation channel, subfamily A, member 1) which can perform an important function in pain (including neuropathic pain) and inflamma

Ramoplanin derivatives possessing antibacterial activity

Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.